View the most recent version.

References

1. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International Journal of Cancer 2007; 121: 621-32.

2. Muñoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003; 348: 518-27.

3. Franceschi S, Clifford GM. Fraction of cervical neoplasias due to human papillomavirus 16 and 18 in vaccine trials. International Journal of Cancer 2008; 122: 719-20.

4. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. Journal of Clinical Microbiology 1995; 33: 2058-63.

5. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693-702.

6. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine 2007; 356: 1928-43.

7. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine 2007; 356: 1915-27.

8. Future II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. Journal of Infectious Diseases 2007; 196: 1438-46.

9. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-70.

10. National Advisory  Committee on Immunization. Statement on human papillomavirus vaccine. An Advisory Committee Statement (ACS). Canada Communicable Disease Report 2007; 33: 1-32.

11. Howlett RI, Miller AB, Pasut G, et al. Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. Preventive Medicine 2009; 48(5): 405-6.

12. Shefer A, Markowitz L, Deeks S, et al. Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia. Vaccine 2008; 26 (Suppl. 10): K68-75.

13. Singh A, Wong T, Howlett RI. Human papillomavirus vaccines: Why the time is right to implement immunization and surveillance programs in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology 2008; 19: 294-6.

14. Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine 2005; 23: 2470-6.

15. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997; 99: 765-73.

16. Young TK, McNicol P, Beauvais J. Factors associated with human papillomavirus infection detected by polymerase chain reaction among urban Canadian aboriginal and non-aboriginal women. Sexually Transmited Diseases 1997; 24: 293-8.

17. Hamlin-Douglas LK, Coutlee F, Roger M, et al. Prevalence and age distribution of human papillomavirus infection in a population of Inuit women in Nunavik, Quebec. Cancer Epidemiology, Biomarkers and Prevention 2008; 17: 3141-9.

18. Morris SK, Nguyen CK. The human papillomavirus vaccine in Canada. Canadian Journal of Public Health 2008; 99: 114-6.

19. Band PR, Gallagher RP, Threlfall WJ, et al. Rate of death from cervical cancer among native Indian women in British Columbia. Canadian Medical Association Journal 1992; 147: 1802-4.

20. Young TK, Kliewer E, Blanchard J, et al. Monitoring disease burden and preventive behavior with data linkage: cervical cancer among aboriginal people in Manitoba, Canada. American Journal of Public Health 2000; 90: 1466-8.

21. Marrett LD, Chaudhry M. Cancer incidence and mortality in Ontario First Nations, 1968-1991 (Canada). Cancer Causes and Control 2003; 14: 259-68.

22. Public Health Agency of Canada. Canadian Immunization Committee. Recommendations on a Human Papillomavirus Immunization Program. Ottawa: Public Health Agency of Canada, 2008.

23. Lee J, Parsons GF, Gentleman JF. Falling short of Pap test guidelines. Health Reports (Statistics Canada, Catalogue 82-003) 1998; 10: 9-19.

24. Snider JA, Beauvais JE. Pap smear utilization in Canada: estimates after adjusting the eligible population for hysterectomy status. Chronic Diseases in Canada 1998; 19: 19-24.

25. Maxwell CJ, Bancej CM, Snider J, et al. Factors important in promoting cervical cancer screening among Canadian women: findings from the 1996-97 National Population Health Survey (NPHS). Canadian Journal of Public Health 2001; 92: 127-33.

26. Johnston GM, Boyd CJ, MacIsaac MA. Community-based cultural predictors of Pap smear screening in Nova Scotia. Canadian Journal of Public Health 2004; 95: 95-8.

27. Mackillop WJ, Zhang-Salomons J, Boyd CJ, et al. Associations between community income and cancer incidence in Canada and the United States. Cancer 2000; 89: 901-12.

28. Ng E, Wilkins R, Fung MF, et al. Cervical cancer mortality by neighbourhood income in urban Canada from 1971 to 1996. Canadian Medical Association Journal 2004; 170: 1545-9.

29. Sauvageau C, Duval B, Gilca V, et al. Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health 2007; 7: 304.

30. Ferris DG, Waller JL, Owen A, et al. Midadult women’s attitudes about receiving the prophylactic human papillomavirus vaccine. Journal of Lower Genital Tract Disease 2007; 11: 166-72.

31. Jain N, Euler GL, Shefer A, et al. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Preventive Medicine 2009; 48(5): 426-31.

32. Haug CJ. Human papillomavirus vaccination--reasons for caution. New England Journal of Medicine 2008; 359: 861-2.

33. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. CA: A Cancer Journal for Clinicians 2007; 57: 7-28.

34. Herzog TJ, Huh WK, Downs LS, et al. Initial lessons learned in HPV vaccination. Gynecologic Oncology 2008; 109: S4-11.

35. Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008; 26(Suppl. 1): A16-23.

36. Franco EL, Cuzick J, Hildesheim A, et al. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006; 24(Suppl. 3): S171-7.

37. Franco EL, Bosch FX, Cuzick J, et al. Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine 2006; 24(Suppl. 3): S242-9.

38. Hildesheim A, Markowitz L, Avila MH, et al. Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. Vaccine 2006; 24(Suppl. 3): S227-32.

39. Ogilvie GS, Remple VP, Marra F, et al. Parental intention to have daughters receive the human papillomavirus vaccine. Canadian Medical Association Journal 2007; 177: 1506-12.

40. Zimet GD, Liddon N, Rosenthal SL, et al. Chapter 24: Psychosocial aspects of vaccine acceptability. Vaccine 2006; 24(Suppl. 3): S201-9.

41. Lehtinen M, Herrero R, Mayaud P, et al. Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 2006; 24(Suppl. 3): S233-41.

42. Lehtinen M, Dillner J. Long-term follow-up (community randomized) vaccination trials facilitates the implementation of human papillomavirus vaccination. HPV Today 2008; 14: 10-1.

43. Kliewer EV, Demers AA, Elliott L, et al. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sexually Transmitted Diseases 2009; 36: 380-6.

44. World Health Organization. Global Advisory Committee on Vaccine Safety, 12-13 June 2007. Weekly Epidemiological Record 2007; 82: 252-9.

45. World Health Organization. Global Advisory Committee on Vaccine Safety, 17-18 December 2008. Weekly Epidemiological Record 2009; 84: 37-40.

46. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367: 489-98.

47. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. Journal of the American Medical Association 2009; 302: 750-7.

48. Brotherton JM, Gold MS. Monitoring vaccine safety: a critical component of every immunisation program. Medical Journal of Australia 2008; 189: 243-4.

49. Brisson M, Van de Velde N, De Wals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25: 5399-408.

50. Brisson M, Van de Velde N, De Wals P, et al. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. Canadian Medical Association Journal 2007; 177: 464-8.

51. Wright TC, Bosch FX, Franco EL, et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine 2006; 24(Suppl. 3): S251-61.

52. Stanley M, Villa LL. Monitoring HPV vaccination. Vaccine 2008;26 Suppl. 1: A24-7.

53. Wheeler CM, Franceschi S. EUROGIN 2007 roadmap—conclusion. Vaccine 2008; 26(Suppl. 1): A28-31.